AAAAAA

   
Results: 1-17 |
Results: 17
Analysis of a natural immune response against tumor antigens in a melanomasurvivor: Lessons applicable to clinical trial evaluations
Authors: Yamshchikov, G Thompson, L Ross, WG Galavotti, H Aquila, W Deacon, D Caldwell, J Patterson, JW Hunt, DF Slingluff, CL
Citation: G. Yamshchikov et al., Analysis of a natural immune response against tumor antigens in a melanomasurvivor: Lessons applicable to clinical trial evaluations, CLIN CANC R, 7(3), 2001, pp. 909S-916S
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
Authors: Slingluff, CL Yamshchikov, G Neese, P Galavotti, H Eastham, S Engelhard, VH Kittlesen, D Deacon, D Hibbitts, S Grosh, WW Petroni, G Cohen, R Wiernasz, C Patterson, JW Conway, BP Ross, WG
Citation: Cl. Slingluff et al., Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes, CLIN CANC R, 7(10), 2001, pp. 3012-3024
Melanoma vaccines (vol 12, pg 163, 2000)
Authors: Brinckerhoff, LH Thompson, LW Slingluff, CL
Citation: Lh. Brinckerhoff et al., Melanoma vaccines (vol 12, pg 163, 2000), CURR OPIN O, 13(5), 2001, pp. 413-413
Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study
Authors: Harlow, SP Krag, DN Ashikaga, T Weaver, DL Meijer, SJ Loggie, BW Tanabe, KK Whitworth, P Kuhn, J Kusminsky, R Carp, NZ Gadd, M Rawlings, M Slingluff, CL
Citation: Sp. Harlow et al., Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study, MELANOMA RE, 11(1), 2001, pp. 45-55
Patient preferences for adjuvant interferon alfa-2b treatment
Authors: Kilbridge, KL Weeks, JC Sober, AJ Haluska, FG Slingluff, CL Atkins, MB Sock, DE Kirkwood, JM Nease, RF
Citation: Kl. Kilbridge et al., Patient preferences for adjuvant interferon alfa-2b treatment, J CL ONCOL, 19(3), 2001, pp. 812-823
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
Authors: Slingluff, CL Colella, TA Thompson, L Graham, DD Skipper, JCA Caldwell, J Brinckerhoff, L Kittlesen, DJ Deacon, DH Oei, C Harthun, NL Huczko, EL Hunt, DF Darrow, TL Engelhard, VH
Citation: Cl. Slingluff et al., Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, CANCER IMMU, 48(12), 2000, pp. 661-672
'Mastectomy'
Authors: Slingluff, CL
Citation: Cl. Slingluff, 'Mastectomy', VA Q REV, 76(4), 2000, pp. 662-663
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells
Authors: Zarour, HM Kirkwood, JM Kierstead, LS Herr, W Brusic, V Slingluff, CL Sidney, J Sette, A Storkus, WJ
Citation: Hm. Zarour et al., Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells, P NAS US, 97(1), 2000, pp. 400-405
Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and-A3
Authors: Yang, SX Kittlesen, D Slingluff, CL Vervaert, CE Seigler, HF Darrow, TL
Citation: Sx. Yang et al., Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and-A3, J IMMUNOL, 164(8), 2000, pp. 4204-4211
Cancer of the male breast
Authors: English, JC Middleton, C Patterson, JW Slingluff, CL
Citation: Jc. English et al., Cancer of the male breast, INT J DERM, 39(12), 2000, pp. 881-886
Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways
Authors: Lippolis, JD Denis-Mize, KS Brinckerhoff, LH Slingluff, CL Galloway, DR Engelhard, VH
Citation: Jd. Lippolis et al., Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways, CELL IMMUN, 203(2), 2000, pp. 75-83
Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy
Authors: Moore, MM Borossa, G Imbrie, JZ Fechner, RE Harvey, JA Slingluff, CL Adams, RB Hanks, JB
Citation: Mm. Moore et al., Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy, ANN SURG, 231(6), 2000, pp. 877-881
Immunology of cancer
Authors: Slingluff, CL
Citation: Cl. Slingluff, Immunology of cancer, SURGERY: BASIC SCIENCE AND CLINICAL EVIDENCE, 2000, pp. 1641-1657
Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms
Authors: Slingluff, CL
Citation: Cl. Slingluff, Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms, CANCER IMMU, 48(7), 1999, pp. 371-373
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998)
Authors: Kittlesen, DJ Thompson, LW Gulden, PH Skipper, JCA Colella, TA Shabanowitz, J Hunt, DF Engelhard, VH Slingluff, CL
Citation: Dj. Kittlesen et al., Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998), J IMMUNOL, 162(5), 1999, pp. 3106-3106
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines
Authors: Brinckerhoff, LH Kalashnikov, VV Thompson, LW Yamshchikov, GV Pierce, RA Galavotti, HS Engelhard, VH Slingluff, CL
Citation: Lh. Brinckerhoff et al., Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines, INT J CANC, 83(3), 1999, pp. 326-334
Mass-spectrometric evaluation of HLA-A0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100
Authors: Skipper, JCA Gulden, PH Hendrickson, RC Harthun, N Caldwell, JA Shabanowitz, J Engelhard, VH Hunt, DF Slingluff, CL
Citation: Jca. Skipper et al., Mass-spectrometric evaluation of HLA-A0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100, INT J CANC, 82(5), 1999, pp. 669-677
Risultati: 1-17 |